NCT03925532View on ClinicalTrials.gov

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

November 16, 2022

Study Completion Date

November 16, 2022

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation RecipientOsteopeniaOsteoporosis

Interventions

BIOLOGICAL

Denosumab

Given SC

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER